Clinical characteristics and treatment of patients with oral lichen planus in Israel.
Oral lichen planus (OLP) has a multiple-site involvement, with the buccal mucosa being the most prevalent. A possible relationship between OLP and the risk of malignancies in the involved site is documented. The characteristics of OLP have been studied in different populations; however, no similar studies have been conducted in any Jewish population. The purpose of this study was to evaluate the natural history of OLP in Israeli Jewish patients. Data were collected from 157 charts of patients with histologically confirmed OLP. No evidence suggesting a connection between OLP and diabetes, cardiovascular disease, smoking, alcohol use, or positive Candida culture was found. Skin involvement of lichen planus was found in one fifth of the patients. Symptomatic OLP was noted in half of the patients, mainly in those with the erosive form. In 65% of the patients with symptoms, improvement by more than 50% was shown within 2 weeks of steroid use. The transformation rate of 1.3% of OLP into malignancy was observed in the entire group. A constant follow-up for contributing symptoms and for early diagnosis of suspected transformed lesions is of utmost importance.
Gorsky
M
M
Section of Oral Pathology and Oral Medicine, Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Israel.
Raviv
M
M
Moskona
D
D
Laufer
M
M
Bodner
L
L
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000150:complications; D002471:Cell Transformation, Neoplastic; D016009:Chi-Square Distribution; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews; D017676:Lichen Planus, Oral / Q000188:drug therapy / Q000208:ethnology / Q000209:etiology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012306:Risk; D012907:Smoking / Q000009:adverse effects
D000305:Adrenal Cortex Hormones